Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors. Despite intensive chemotherapy, 20% of pediatric patients and over 50% of adult patients with ALL do not achieve a complete remission or relapse after intensified chemotherapy, making disease relapse and resistance to therapy the most substantial challenge in the treatment of this disease 1,2 . Using whole-exome sequencing, we identify mutations in the cytosolic 5′-nucleotidase II gene (NT5C2), which encodes a 5′-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs. NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL lymphoblasts. These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.
Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors. Despite intensive chemotherapy, 20% of pediatric patients and over 50% of adult patients with ALL do not achieve a complete remission or relapse after intensified chemotherapy, making disease relapse and resistance to therapy the most substantial challenge in the treatment of this disease 1, 2 . Using whole-exome sequencing, we identify mutations in the cytosolic 5′-nucleotidase II gene (NT5C2), which encodes a 5′-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs. NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL lymphoblasts. These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.
Therapy for ALL includes an initial treatment with high-dose combination chemotherapy, which results in clinical and hematologic remission in over 90% of cases. This is typically followed by additional rounds of highly intensive therapy aimed at further reducing disease burden and then a 2-year-long lower-intensity maintenance therapy in which treatment with oral 6-mercaptopurine (6-MP) has a particularly important role 3, 4 . Patients with relapsed ALL generally receive more intense treatment. However, despite these efforts, the outcome of these patients remains unsatisfactory, with cure rates of less than 40% 5 . This is the case particularly in patients with relapsed T cell ALL (T-ALL) and in individuals with primary resistance or early relapse, which is associated with a higher risk of failure to achieve a second complete remission, shorter duration of chemotherapy response and poor survival 6, 7 . Much effort has been directed toward the study of the molecular basis of relapse and chemotherapy resistance in ALL. However, the specific mechanisms mediating escape from therapy, disease progression and leukemia relapse remain largely unknown. To address this issue, we performed whole-exome sequencing of matched diagnosis, remission and relapse DNA samples from five pediatric patients with T-ALL ( Supplementary Table 1 ). This analysis identified a mean mutation load of 13 (range, 5-17) somatic mutations per sample (Supplementary Table 2 ). Out of 60 somatic mutations identified in total, 17 were present at diagnosis and relapse, 24 genes were selectively mutated in relapsed T-ALL samples and 19 mutations were present only at diagnosis. Moreover, four of the five relapsed leukemias analyzed showed the presence of at least one somatic mutation at diagnosis together with secondary mutations specifically acquired at the time of relapse. In addition, four out of these five individuals showed absence of at least one mutation marker present at diagnosis during disease progression leading to relapse. Single-nucleotide polymorphism (SNP) analysis of the exome sequencing results ruled out that loss of these markers was caused by loss of heterozygosity at relapse ( Supplementary Table 3 ). This result is consistent with previous studies based on copy number alteration analyses [8] [9] [10] and supports that relapsed ALLs can originate as derivates of ancestral subclones related to, but distinct from, the main leukemic population present at diagnosis.
Somatically mutated genes at diagnosis included known T-ALL tumor suppressor genes, such as FBXW7 (ref. 11), WT1 (ref. 8 ) and DNM2 (ref. 12) , in addition to numerous new genes not previously implicated in the pathogenesis of this disease. Analysis of mutant alleles found at the time of relapse identified mutations in three genes encoding proteins involved in positive regulation of TP53 signaling, including TP53 itself (R213Q), BANP (H391Y) 13 and RPL11 a b R367Q   1  2  8  7  6  5  4  3   3 5  3 9 2  17  16  15  14  13  12  11 10 9
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(R18P) 14 (Supplementary Fig. 1 ). Notably, mutations in TP53 have been reported in ~10% of relapsed patients with ALL and are associated with a particularly poor prognosis 15 . Given the prominent role of the TP53 pathway in DNA damage-induced apoptosis 16 , we performed extended mutation analysis of TP53, BANP and RPL11 in 18 additional diagnostic and relapsed T-ALL samples ( Supplementary  Table 1 ). This analysis did not identify additional TP53 or BANP mutations but did show the presence of two additional somatic RPL11 mutant alleles: one (X178Q) was present both at diagnosis and relapse, and the other (G30fs) was specifically mutated at relapse. Relapseassociated mutations also included a prototypical activating mutation in the NRAS oncogene (G13V). Notably, NRAS mutations in ALL have been associated with poor outcome 17 and are particularly prevalent in early T cell-precursor ALLs 12,18 , a group of high-risk leukemias with poor prognosis 19 . Extended mutation analysis of NRAS in relapsed patients with T-ALL showed the presence of two diagnostic and relapse sample pairs harboring a prototypical NRAS G12S activating allele and a third patient with a heterozygous activating NRAS G12R mutation, which was present at diagnosis and showed loss of heterozygosity at the time of relapse.
However, the most notable finding in our exome sequence analysis was the presence of a relapse-associated heterozygous mutation in NT5C2 (K359Q). NT5C2 is a ubiquitous enzyme that is responsible for the final dephosphorylation of 6-hydroxypurine nucleotide monophosphates such as inosine monophosphate (IMP), deoxyinosine monophosphate (dIMP), guanosine monophosphate (GMP), dGMP and xanthosine monophosphate (XMP) before they can be exported out of the cell 20, 21 . In addition, and most notably, NT5C2 can also dephosphorylate and inactivate 6-thioinositol monophosphate and 6-thioguanosine monophosphate, which mediate the cytotoxic effects of 6-MP and 6-thioguanine (6-TG) 22 , two nucleoside analogs commonly used in the treatment of ALL. Mutation analysis of an extended panel of 98 relapse T-ALL and 35 relapse B-precursor ALL samples ( Supplementary Table 1 ) identified 22 additional mutations in T-ALL and one additional NT5C2 npg mutation in a patient with B-precursor ALL in first relapse ( Fig. 1 and Supplementary Table 4 ). Notably, 13 of these samples harbored the same NT5C2 R367Q mutation, 4 showed a recurrent NT5C2 R238W mutation and 2 harbored a L375F single-amino acid substitution ( Fig. 1 and Supplementary Table 4 ). In each of the nine individuals for which original diagnostic DNA was available for analysis, the NT5C2 mutations were specifically acquired at the time of relapse. We identified no NT5C2 mutations in an additional 23 T-ALL and 27 B-precursor ALL diagnostic samples, further supporting the specific association of NT5C2 mutations with relapsed disease. Analysis of clinical and molecular features associated with NT5C2-mutant relapsed T-ALLs treated in the Berlin Frankfurt Münster (BFM) group-based clinical trials ( Supplementary  Table 1 ) showed an association of NT5C2 mutations with early disease recurrence (very early or early relapse compared to late relapse, P < 0.05) and relapse under treatment (P = 0.002) independent of the upfront treatment protocol (Supplementary Tables 5-10).
Given the described role of NT5C2 in the metabolism and inactivation of nucleoside-analog drugs [22] [23] [24] , the recurrent finding of the NT5C2 R367Q, R238W and L375F alleles and the reported association of increased amounts of nucleotidase activity with thiopurine resistance and worse clinical outcome 25 , we hypothesized that relapseassociated NT5C2 mutations may represent gain-of-function alleles with increased enzymatic activity. Detailed structure-function analysis of the NT5C2 K359Q mutation further supported this hypothesis. Comparison of the wild-type NT5C2 structure and models of the mutant NT5C2 K359Q protein showed that this mutation could result in increased NT5C2 activity by mimicking the effect of positive allosteric regulators ( Fig. 2a) . Allosteric activation of NT5C2 is mediated by binding of ATP, dATP, diadenosine tetraphosphate (Ap 4 A) and 2,3-bisphosphoglyceric acid (BPG) to an allosteric pocket proximal to the NT5C2 active site ( Fig. 2a) . Occupancy of this regulatory site results in increased ordering of an α-helix formed by residues Gly355-Glu364 (helix A), which in turn displaces Phe354 from the catalytic center and moves Asp356 into the active site of the protein (Fig. 2b,c) . Similarly, our model predicts that the NT5C2 K359Q mutation could increase the stability of helix A and reduce its solvent accessibility, resulting in an active configuration with displacement of Phe354 out of the NT5C2 active site and positioning Asp356 into the catalytic center of the enzyme ( Fig. 2b-e ). Consistent with this prediction, 5′-nucleotidase (5′-NT) assays using a NT5C2 K359Q recombinant protein showed a 48-fold increase in enzymatic activity compared to wild-type NT5C2 (Fig. 3) . An additional structurally interesting allele is the NT5C2 Q523* nonsense mutation, which removes an inhibitory region located in the C-terminal segment of the NT5C2 protein 26 . In addition, and despite the absence of clear structural cues suggesting a role of other mutations in NT5C2 activation, nucleotidase activity analysis of NT5C2 R367Q and D407A mutant proteins revealed an 18-fold and a 16-fold increase in their 5′-IMP nucleotidase activity compared with wild-type NT5C2, respectively ( Fig. 3) .
To formally test the role of NT5C2 mutations in chemotherapy resistance, we analyzed the effects of wild-type and relapse-associated mutant NT5C2 expression in the response of CCRF-CEM T-ALL cells to 6-MP and 6-TG ( Fig. 4) . Cell viability analysis in the presence of increasing drug concentrations demonstrated increased resistance to 6-MP and 6-TG therapy in cells expressing K359Q, R367Q and D407A NT5C2 compared with empty vector and wild-type NT5C2 controls ( Fig. 4, Supplementary Fig. 2 and Supplementary Table 11 ). We obtained similar results in the CUTLL1 T-ALL cell line ( Fig. 4,  Supplementary Fig. 2 and Supplementary Table 11 ). We then tested the effects of relapse-associated NT5C2 mutations in the response to nelarabine, an arabinosylguanine (AraG) precursor that is highly active in relapsed T-ALL, and AraG [27] [28] [29] [30] . Notably, both nelarabine and AraG were equally active in cells expressing relapse-associated NT5C2 mutations compared to controls (Supplementary Fig. 3) .
Prolonged maintenance treatment with 6-MP is essential to obtain durable remissions in the treatment of ALL 3, 4 . Indeed, low adherence to 6-MP treatment, defined as less than 95% compliance, results in increased relapsed rates and may account for as many as 59% of all ALL relapses 31 . In this context, our results highlight the prominent role of relapse-specific mutations in NT5C2 as a mechanism of resistance to 6-MP and a genetic driver of relapse in ALL. In addition, and most notably, a lack of nelarabine crossresistance in the cells expressing activating NT5C2 alleles analyzed here suggests that these mutations may not impair the effectiveness of nelarabine-based salvage therapies in relapsed T-ALL.
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Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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Whole-exome capture and next generation sequence analysis. We used matched diagnostic remission and relapsed DNA samples from five patients with T-ALL from the University of Padua treated under Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) protocols ( Supplementary  Table 1 ) for exome capture with the SureSelect 50 Mb All Exon kit (Agilent Technologies) following standard protocols. We performed paired-end sequencing (2 × 100 bp) by using HiSeq2000 sequencing instruments at Centrillion Biosciences. Illumina HiSeq analysis produced between 60 million and 120 million paired-end reads per sample. We mapped reads to the reference genome hg19 using the Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9. The mean depth (defined as the mean number of reads covering the captured coding sequence of a haploid reference) was 50×, with 80% of the genome covered more than 10× and 57% covered more than 30×. We identified sites that differed from the reference (called here variants) in each sample independently. We constructed empirical priors for the distribution of variant frequencies for each sample. We obtained high-credibility intervals (posterior probability ≥1-10 -5 ) for the corresponding change in frequency between tumor and normal samples using the SAVI (Statistical Algorithm for Variant Identification) algorithm developed at Columbia University 32, 33 . The number of germline SNPs in the coding region was 18,000, which is comparable with previous reports 32 . Most of the candidate germline SNPs (16,000, or ~90% of germline variants) were reported in the dbSNP database. We identified candidate somatic variants using the following criteria: variant total depth in tumor and normal >10× and <300×, variant frequency >15% in tumor and <3% in normal and ≥1% change in frequency from the normal with high posterior probability (≥1-10 -5 ). Also, to remove systematic errors, we excluded all variants that were found in unaffected individuals. In addition, to eliminate ambiguous mapping from captured pseudogenes and regions of low complexity, each variant with a flanking 20-base context sequence around its genomic position was mapped to the hg19 reference using the BLAST algorithm. We kept in the list only those with unique mappability; that is, we required the 41-base sequence to uniquely map to the reference genome with only one mismatch.
To discern the regions of loss of heterozygosity (LOH), we used the SAVIcalculated high-credibility intervals for the variants in dbSNP, which correspond to the change in their frequency between tumor and normal samples. In an LOH event, depending on whether the reference or the dbSNP allele was lost, at least a 1% or at most a −1% change in frequency from the normal is expected. Therefore, by segmenting the regions covering more than ten dbSNP variants with significantly changed frequencies, we were able to identify the LOH regions.
Mutation validation and analysis of recurrence. We designed primers flanking exons containing candidate somatic variants using Primer3 (http://frodo. wi.mit.edu/primer3/) and used them for PCR amplification from whole genome-amplified (WGA) tumor, relapse and matched normal (remission) DNAs. We analyzed the resulting amplicons by direct bidirectional dideoxynucleotide sequencing with a validation rate of 97%. After exome sequence analysis of 5 diagnostic relapse and remission T-ALL AIEOP samples from the University of Padua (Supplementary Table 1) , we used 18 additional patient samples from the same institution for the analysis of recurrence of TP53, BANP, RPL11, NRAS and NT5C2 (Supplementary Table 1) .
We subsequently extended this series to additional relapse T-ALL samples from the University of Padua (n = 13) and the Charité-Universitätsmedizin Berlin (n = 67) ( Supplementary Table 1 ) and to relapsed patients with B-precursor ALL from the University of Padua (n = 35) for extended mutation analysis of NT5C2 ( Supplementary Table 1 ). We used two cohorts of diagnostic patients with T-ALL from ECOG (n = 23) and diagnostic patients with B-precursor ALL from the University of Padua (n = 27) to verify the absence of NT5C2 mutations in diagnostic ALL specimens (Supplementary Table 1) .
Structural depiction and analysis. We identified structural coverage of the NT5C2 protein through use of the PSI-Blast and SKAN algorithms; we subsequently mapped viable structures to all NT5C2 isoforms and analyzed them using Chimera Suite 34, 35 . We aligned structurally the PDB structures 2XCW, 2XCX, 2XCB, 2XCV, 2XJB, 2XJC, 2XJD, 2XJE, 2XJF, 2J2C and 2JC9 and subsequently analyzed the composite structure to assess conformational flexibilities 34 . We structurally modeled NT5C2 mutations using the I-TASSER software suite and subsequently refined and analyzed them by minimization and rotamer library analysis in Chimera 34, 36 . We predicted protein stability changes resulting from mutation through use of the SDM potential energy statistical algorithm and associated software 37 . We created all structural images using UCSF Chimera 34 .
Site-directed mutagenesis. We generated the NT5C2 mutations K359Q, R367Q and D407A by site-directed mutagenesis on the mammalian expression pLOC-NT5C2 vector (Open Biosystems) using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instructions.
Cell lines. We cultured CCRF-CEM and CUTLL1 cells in RPMI-1640 medium supplemented with 10% FBS, 100 U ml −1 penicillin G and 100 µg ml −1 streptomycin at 37 °C in a humidified atmosphere under 5% CO 2 . We maintained HEK293T cells under similar conditions in DMEM media. Lentiviral production and infection. We transfected the lentiviral constructs pLOC-NT5C2, pLOC-NT5C2-359, pLOC-NT5C2-367 and pLOC-NT5C2-407 and the pLOC-RFP control plasmid with Gag-Pol-and V-SVG-expressing vectors into HEK293T cells using JetPEI transfection reagent (Polyplus). We collected viral supernatants after 48 h and used them for infection of CCRF-CEM and CUTLL1 cells by spinoculation. After infection, we selected cells for 5 d in blasticidin and ficolled them the day before experiments.
Western blot. Western blot analysis was performed using a rabbit polyclonal antibody to NT5C2 (1:1,000, Abcam, ab96084) and a goat polyclonal antibody to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1,000, Santa Cruz Biotechnology, sc-20357) using standard procedures.
Cell viability and chemotherapy drug response. We determined cell viability by measurement of the metabolic reduction of the tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) following the manufacturer's instructions. We performed experiments in triplicate. We analyzed viability at 48 h or 72 h after initiation of treatment with 6-MP, 6-TG, nelarabine and AraG.
Recombinant protein production and purification. We cloned full-length complementary DNA constructs encoding wild-type, K359Q, R367Q and D407A NT5C2 with an N-terminal hexahistidine (His 6 ) tag in the pET28a-LIC expression vector using the In-Fusion HD PCR cloning system (Clontech) as per the manufacturer's instructions. We expressed recombinant proteins from Rosetta 2(DE3) Escherichia coli cells by induction with 0.5 mM isopropyl-β-d-thiogalactopyranoside for 3 h at 37 °C. We harvested cells and lysed them in lysis buffer (50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol, 1% Triton X-100, 0.5 mg ml −1 lysozyme and 20 mM imidazole) supplemented with Complete EDTA-free protease inhibitor (Roche). We purified His 6 -tagged NT5C2 proteins by binding them to nickel-Sepharose beads and eluting them with 50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol and 300 mM imidazole. We removed imidazole by buffer npg exchange using PD-10 desalting columns (GE Healthcare). We assessed protein expression and purity by SDS-PAGE and Coomassie staining.
5′-NT assay. We assessed 5′-NT activity of purified recombinant wild-type and mutant NT5C2 proteins using the 5′-NT Enzymatic Test Kit (Diazyme) according to the manufacturer's instructions. The assay measures the enzymatic hydrolysis of inosine 5′-monophosphate to inosine, which is reacted further to hypoxanthine by purine nucleoside phosphorylase and then to uric acid and hydrogen peroxide by xanthine oxidase. H 2 O 2 is quantified using a Trinder reaction. We calculated 5′-NT activity levels using a calibrator of known 5′-NT activity as standard. We performed assays in triplicate in an Infinite M200 Tecan plate reader.
Statistical analyses. We evaluated differences in the percentages of wild-type and mutant NT5C2 in patients with ALL in different relapsed categories using Fisher's exact test. We analyzed the equality of categorical and continuous variables by Fisher's exact test and Mann-Whitney U test, respectively.
